

David G Denardo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4146115/publications.pdf>

Version: 2024-02-01

82
papers

17,728
citations

57758

44
h-index

64796

79
g-index

93
all docs

93
docs citations

93
times ranked

23587
citing authors

#	ARTICLE	IF	CITATIONS
1	Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma. JCI Insight, 2022, 7, .	5.0	22
2	MITI minimum information guidelines for highly multiplexed tissue images. Nature Methods, 2022, 19, 262-267.	19.0	37
3	IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2022, 162, 2047-2062.	1.3	18
4	Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS. Cancers, 2022, 14, 2153.	3.7	5
5	Single-cell profiling of human dura and meningioma reveals cellular meningeal landscape and insights into meningioma immune response. Genome Medicine, 2022, 14, 49.	8.2	37
6	Rethinking immune checkpoint blockade: "Beyond the T cell"™. , 2021, 9, e001460.		76
7	Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors. Cell Reports, 2021, 35, 108944.	6.4	44
8	GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. , 2021, 9, e003005.		22
9	Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment. Journal of Clinical Investigation, 2021, 131, .	8.2	42
10	Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 6761-6771.	7.0	33
11	Abstract IA-002: Dendritic cell corner stone of tumor immunity in PDAC. , 2021, , .		0
12	Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. Gut, 2020, 69, 122-132.	12.1	89
13	Tumor Microenvironment as a Regulator of Radiation Therapy: New Insights into Stromal-Mediated Radioresistance. Cancers, 2020, 12, 2916.	3.7	63
14	Increased Mutational Burden Sensitizes Pancreatic Cancer to Anti-Tumor Effects of Immunotherapy. Journal of the American College of Surgeons, 2020, 231, S161-S162.	0.5	0
15	Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor. American Journal of Surgical Pathology, 2020, 44, 817-825.	3.7	1
16	Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer. Frontiers in Oncology, 2020, 10, 748.	2.8	20
17	Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell, 2020, 37, 289-307.e9.	16.8	252
18	B cell-Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Cancer Immunology Research, 2020, 8, 292-308.	3.4	62

#	ARTICLE	IF	CITATIONS
19	A framework for advancing our understanding of cancer-associated fibroblasts. <i>Nature Reviews Cancer</i> , 2020, 20, 174-186.	28.4	2,012
20	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020, 181, 236-249.	28.9	334
21	Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity. <i>JCI Insight</i> , 2020, 5, .	5.0	12
22	A Single-Cell Window into Pancreas Cancer Fibroblast Heterogeneity. <i>Cancer Discovery</i> , 2019, 9, 1001-1002.	9.4	17
23	Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	148
24	Myeloid-Derived Lymphatic Endothelial Cell Progenitors Significantly Contribute to Lymphatic Metastasis in Clinical Breast Cancer. <i>American Journal of Pathology</i> , 2019, 189, 2269-2292.	3.8	24
25	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
26	Macrophages as regulators of tumour immunity and immunotherapy. <i>Nature Reviews Immunology</i> , 2019, 19, 369-382.	22.7	1,365
27	IRAK4 mediates colitis-induced tumorigenesis and chemoresistance in colorectal cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	26
28	Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. <i>Oncotarget</i> , 2019, 10, 4761-4775.	1.8	45
29	Better Together: B7S1 Checkpoint Blockade Synergizes with anti-PD1. <i>Immunity</i> , 2018, 48, 621-623.	14.3	4
30	Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. <i>Nature Communications</i> , 2018, 9, 1250.	12.8	151
31	Targeting both tumour-associated CXCR2 ⁺ neutrophils and CCR2 ⁺ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. <i>Gut</i> , 2018, 67, 1112-1123.	12.1	334
32	Recruitment of CCR2 ⁺ tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer. <i>Oncotarget</i> , 2018, 7, e1470729.	4.6	88
33	SNAIL1 action in tumor cells influences macrophage polarization and metastasis in breast cancer through altered GM-CSF secretion. <i>Oncogenesis</i> , 2018, 7, 32.	4.9	46
34	STAT3 signaling mediates FAK inhibitor response and resistance in pancreatic cancer. <i>FASEB Journal</i> , 2018, 32, 281.4.	0.5	0
35	Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1037-1048.	4.2	164
36	Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. <i>Immunity</i> , 2017, 47, 323-338.e6.	14.3	499

#	ARTICLE	IF	CITATIONS
37	Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 1748-1759.	7.0	56
38	Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. <i>Nature Medicine</i> , 2016, 22, 851-860.	30.7	738
39	Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 651-662.	10.7	557
40	Antagonizing Integrin $\alpha 2 \beta 3$ Increases Immunosuppression in Cancer. <i>Cancer Research</i> , 2016, 76, 3484-3495.	0.9	58
41	Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. <i>Journal of Experimental Medicine</i> , 2016, 213, 827-840.	8.5	114
42	Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. <i>Nature Communications</i> , 2016, 7, 11762.	12.8	290
43	The Action of Discoidin Domain Receptor 2 in Basal Tumor Cells and Stromal Cancer-Associated Fibroblasts Is Critical for Breast Cancer Metastasis. <i>Cell Reports</i> , 2016, 15, 2510-2523.	6.4	85
44	Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. <i>Journal of Cell Biology</i> , 2016, 213, 2131OIA66.	5.2	1
45	Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis. <i>Journal of Clinical Investigation</i> , 2016, 126, 1458-1470.	8.2	62
46	Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. <i>Oncotarget</i> , 2016, 7, 33529-33541.	1.8	21
47	TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 518-525.	3.4	197
48	Reprogramming myeloid responses to improve cancer immunotherapy. <i>Oncotarget</i> , 2015, 4, e974399.	4.6	9
49	Paclitaxel Therapy Promotes Breast Cancer Metastasis in a TLR4-Dependent Manner. <i>Cancer Research</i> , 2014, 74, 5421-5434.	0.9	196
50	CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models. <i>Cancer Research</i> , 2014, 74, 5057-5069.	0.9	1,030
51	Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 513-528.	4.2	185
52	Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses. <i>Cancer Research</i> , 2013, 73, 1128-1141.	0.9	797
53	Targeting tumor-infiltrating macrophages to combat cancer. <i>Immunotherapy</i> , 2013, 5, 1075-1087.	2.0	135
54	Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis. <i>Clinical Cancer Research</i> , 2013, 19, 3404-3415.	7.0	473

#	ARTICLE	IF	CITATIONS
55	Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. <i>Genes and Development</i> , 2013, 27, 2086-2098.	5.9	74
56	Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models. <i>PLoS ONE</i> , 2013, 8, e77243.	2.5	36
57	A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Journal of Cancer Therapy</i> , 2013, 04, 797-803.	0.4	26
58	Battle over CCL2 for control of the metastatic niche: neutrophils versus monocytes. <i>Breast Cancer Research</i> , 2012, 14, 315.	5.0	14
59	Tumor-infiltrating macrophages, cancer stem cells and therapeutic responses. <i>Oncotarget</i> , 2012, 3, 1497-1498.	1.8	2
60	MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles. <i>Clinical Cancer Research</i> , 2011, 17, 5695-5704.	7.0	262
61	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. <i>Cancer Discovery</i> , 2011, 1, 54-67.	9.4	1,486
62	Labeling Human Embryonic Stem Cell-Derived Cardiomyocytes with Indocyanine Green for Noninvasive Tracking with Optical Imaging: An FDA-Compatible Alternative to Firefly Luciferase. <i>Cell Transplantation</i> , 2010, 19, 55-65.	2.5	29
63	Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 309-316.	5.9	427
64	FcR γ Activation Regulates Inflammation-Associated Squamous Carcinogenesis. <i>Cancer Cell</i> , 2010, 17, 121-134.	16.8	537
65	Macrophage Expression of Hypoxia-Inducible Factor-1 α Suppresses T-Cell Function and Promotes Tumor Progression. <i>Cancer Research</i> , 2010, 70, 7465-7475.	0.9	542
66	Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response. <i>Cancer Research</i> , 2010, 70, 7776-7787.	0.9	25
67	Lymphocytes in cancer development: Polarization towards pro-tumor immunity. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 3-10.	7.2	198
68	Labeling human embryonic stem cell-derived cardiomyocytes with indocyanine green for noninvasive tracking with optical imaging: an FDA-compatible alternative to firefly luciferase. <i>Cell Transplantation</i> , 2010, 19, 55-65.	2.5	19
69	CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages. <i>Cancer Cell</i> , 2009, 16, 91-102.	16.8	1,135
70	Optical imaging of the peri-tumoral inflammatory response in breast cancer. <i>Journal of Translational Medicine</i> , 2009, 7, 94.	4.4	6
71	Immune cells as mediators of solid tumor metastasis. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 11-18.	5.9	326
72	Polarized immune responses differentially regulate cancer development. <i>Immunological Reviews</i> , 2008, 222, 145-154.	6.0	172

#	ARTICLE	IF	CITATIONS
73	Inflaming Gastrointestinal Oncogenic Programming. <i>Cancer Cell</i> , 2008, 14, 7-9.	16.8	28
74	Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. <i>Molecular and Cellular Endocrinology</i> , 2007, 277, 13-25.	3.2	32
75	Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. <i>Breast Cancer Research</i> , 2007, 9, 212.	5.0	584
76	Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 121-134.	2.5	115
77	Identification of Biomarkers Modulated by the Retinoid LGD1069 (Bexarotene) in Human Breast Cells Using Oligonucleotide Arrays. <i>Cancer Research</i> , 2006, 66, 12009-12018.	0.9	45
78	The Retinoid X Receptor-Selective Retinoid, LGD1069, Down-regulates Cyclooxygenase-2 Expression in Human Breast Cells through Transcription Factor Crosstalk: Implications for Molecular-Based Chemoprevention. <i>Cancer Research</i> , 2005, 65, 3462-3469.	0.9	56
79	Global Gene Expression Analysis of Estrogen Receptor Transcription Factor Cross Talk in Breast Cancer: Identification of Estrogen-Induced/Activator Protein-1-Dependent Genes. <i>Molecular Endocrinology</i> , 2005, 19, 362-378.	3.7	99
80	Anti-HLA-DR/anti-DOTA Diabody Construction in a Modular Gene Design Platform: Bispecific Antibodies for Pretargeted Radioimmunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2001, 16, 525-535.	1.0	23
81	Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 4000-4004.	7.1	93
82	Marine World Africa USA Shark Experience. <i>International Zoo Yearbook</i> , 1995, 34, 87-95.	0.9	2